

## **Report from the meeting "Soft Tissue Sarcoma in the Young"**

**Stuttgart, December 16th, 2016**

The meeting was held by the CWS group celebrating their 35-year anniversary. It was also a tribute to Ewa Koscielniak who recently retired.

The main topics were as follows:

- Global achievements and further perspectives in RMS. The new FaR-RMS protocol was discussed. This will be a protocol for both children and adults, with no upper age limit. It is a complex protocol with several risk groups and different treatments, including randomized phase III studies. University of Birmingham will be the sponsor and it is expected to open 2018/2019.
- Non-rhabdo soft tissue sarcoma, and especially synovial sarcoma. The new EuroJoss protocol was discussed. This will also be a joint protocol for children and young adults. Discussions with Bayer about including regorafenib as one of the drugs are ongoing. It has not been decided how to solve the logistics (e.g. sponsor) and economic issues. SSG is included as a partner and will be a part of further discussions.
- Pathology and molecular biology of RMS (and some NRSTS).

Kjetil Boye  
December 21<sup>st</sup> 2016